Galapagos presented new data at icml 2025 from cohort 3 of atalanta-1 in relapsed/refractory indolent nhl patients, demonstrating high complete response and mrd negativity rates with car-t candidate glpg5101

Of the 34 patients enrolled in cohort 3 of the atalanta-1 phase 1/2 study, 32 received glpg5101; 94% were infused with fresh car-t cells, and 93% were treated within seven days of manufacturing

CAR Ratings Summary

CAR Quant Ranking